Ekso Bionics to effect 1-for-15 reverse stock split

Ekso Bionics announced that it will effect a reverse stock split of shares of its common stock at a ratio of 1-for-15, effective as of May 27at 12:01 a.m. Pacific time. The company’s common stock will open for trading on Nasdaq Capital Market on May 27 on a split-adjusted basis under the existing symbol (EKSO). The company’s common stock will trade under a new CUSIP number 282644 400 upon the effectiveness of the reverse stock split. Upon the effectiveness of the reverse stock split, the number of shares of the company’s outstanding common stock will decrease from approximately 35,289,695 pre-split shares to approximately 2,352,646 post-split shares, with no change in par value per share. The reverse stock split was approved by the company’s shareholders at a special meeting held on May 16, 2025, and is primarily intended to raise the per share trading price of the Company’s common stock and, in particular, enable the Company to regain compliance with the minimum bid price requirement for maintaining its listing on The Nasdaq Capital Market. To regain compliance, the closing bid price of the company’s common stock must be at least $1.00 for a minimum of ten consecutive trading days.